PTC scores new Emflaza approval in DMD patients 2 and older

10th June 2019 Uncategorised 0

Duchenne muscular dystrophy drug Emflaza drew fire after it was first approved for its $85,000 price tag. Now, the drug has a new owner, a new list price—$35,000 after discounts—and an expanded label, thanks to an FDA approval in younger boys.

More: PTC scores new Emflaza approval in DMD patients 2 and older
Source: fierce